Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was th...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Lippincott, Williams & Wilkins
2020
|
| _version_ | 1826257938545639424 |
|---|---|
| author | St Jean, PL Koh, GCKW Breton, JJ Espino, FEJ Hien, TT Krudsood, S Lacerda, MVG Llanos-Cuentas, A Lon, C Mohammed, R Namaik-Larp, CS Pereira, DB Saunders, DL Velez, ID Yilma, D Villegas, MF Duparc, S Green, JA |
| author_facet | St Jean, PL Koh, GCKW Breton, JJ Espino, FEJ Hien, TT Krudsood, S Lacerda, MVG Llanos-Cuentas, A Lon, C Mohammed, R Namaik-Larp, CS Pereira, DB Saunders, DL Velez, ID Yilma, D Villegas, MF Duparc, S Green, JA |
| author_sort | St Jean, PL |
| collection | OXFORD |
| description | Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity against P. vivax hypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria in patients 16 years and older. We conducted an exploratory pharmacogenetic analysis (GSK Study 208099) to assess the role of host genome-wide variation on tafenoquine efficacy in patients with P. vivax malaria using data from three GSK clinical trials, GATHER and DETECTIVE Part 1 and Part 2. Recurrence-free efficacy at 6 and 4 months and time to recurrence up to 6 months postdosing were analyzed in 438 P. vivax malaria patients treated with tafenoquine. Among the approximately 10.6 million host genetic variants analyzed, two signals reached genome-wide significance (P value ≤ 5 × 10−8). rs62103056, and variants in a chromosome 12 intergenic region, were associated with recurrence-free efficacy at 6 and 4 months, respectively. Neither of the signals has an obvious biological rationale and would need replication in an independent population. This is the first genome-wide association study to evaluate genetic influence on response to tafenoquine in P. vivax malaria. |
| first_indexed | 2024-03-06T18:26:07Z |
| format | Journal article |
| id | oxford-uuid:0801ef22-93b2-40ec-8989-b81e6426a2c7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:26:07Z |
| publishDate | 2020 |
| publisher | Lippincott, Williams & Wilkins |
| record_format | dspace |
| spelling | oxford-uuid:0801ef22-93b2-40ec-8989-b81e6426a2c72022-03-26T09:10:40ZPharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malariaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0801ef22-93b2-40ec-8989-b81e6426a2c7EnglishSymplectic ElementsLippincott, Williams & Wilkins2020St Jean, PLKoh, GCKWBreton, JJEspino, FEJHien, TTKrudsood, SLacerda, MVGLlanos-Cuentas, ALon, CMohammed, RNamaik-Larp, CSPereira, DBSaunders, DLVelez, IDYilma, DVillegas, MFDuparc, SGreen, JAPlasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity against P. vivax hypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria in patients 16 years and older. We conducted an exploratory pharmacogenetic analysis (GSK Study 208099) to assess the role of host genome-wide variation on tafenoquine efficacy in patients with P. vivax malaria using data from three GSK clinical trials, GATHER and DETECTIVE Part 1 and Part 2. Recurrence-free efficacy at 6 and 4 months and time to recurrence up to 6 months postdosing were analyzed in 438 P. vivax malaria patients treated with tafenoquine. Among the approximately 10.6 million host genetic variants analyzed, two signals reached genome-wide significance (P value ≤ 5 × 10−8). rs62103056, and variants in a chromosome 12 intergenic region, were associated with recurrence-free efficacy at 6 and 4 months, respectively. Neither of the signals has an obvious biological rationale and would need replication in an independent population. This is the first genome-wide association study to evaluate genetic influence on response to tafenoquine in P. vivax malaria. |
| spellingShingle | St Jean, PL Koh, GCKW Breton, JJ Espino, FEJ Hien, TT Krudsood, S Lacerda, MVG Llanos-Cuentas, A Lon, C Mohammed, R Namaik-Larp, CS Pereira, DB Saunders, DL Velez, ID Yilma, D Villegas, MF Duparc, S Green, JA Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title_full | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title_fullStr | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title_full_unstemmed | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title_short | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria |
| title_sort | pharmacogenetic assessment of tafenoquine efficacy in patients with plasmodium vivax malaria |
| work_keys_str_mv | AT stjeanpl pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT kohgckw pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT bretonjj pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT espinofej pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT hientt pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT krudsoods pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT lacerdamvg pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT llanoscuentasa pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT lonc pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT mohammedr pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT namaiklarpcs pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT pereiradb pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT saundersdl pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT velezid pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT yilmad pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT villegasmf pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT duparcs pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria AT greenja pharmacogeneticassessmentoftafenoquineefficacyinpatientswithplasmodiumvivaxmalaria |